How to Build a Release Testing Strategy for Cell Therapy Products
A well-designed Release Testing strategy is essential for determining whether a cell therapy product meets predefined quality requirements before it is released for its intended use. Unlike conventional pharmaceuticals, cell therapies are complex biological products, and their quality can be influenced by starting material variability, manufacturing conditions, processing time, and storage.
For biotechnology and pharmaceutical companies, Release Testing should not be treated as the final isolated step in manufacturing. The strongest strategy connects release assays with in-process testing, process knowledge, product characterization, and Good Manufacturing Practice controls. This creates a more complete understanding of product quality and helps reduce the risk of discovering critical issues only after manufacturing is complete.
What Is Release Testing for Cell Therapy Products?
Release Testing refers to the analytical and quality control activities used to confirm that a manufactured batch meets established specifications before release.
The specific tests depend on the product, manufacturing process, stage of development, and applicable regulatory expectations.
A release testing strategy may assess:
- Identity
- Purity
- Viability
- Potency
- Sterility
- Mycoplasma
- Endotoxin
- Cell number or concentration
- Product-specific functional characteristics
Each test should provide meaningful information about a critical aspect of product quality.
Start With the Product's Critical Quality Attributes
The foundation of a release strategy is a clear understanding of the product's critical quality attributes, or CQAs.
CQAs are characteristics that should be controlled to support the product's intended quality, safety, and performance.
For a cell therapy, relevant CQAs may include:
Identity
Does the product contain the intended cell population?
Purity
Are unwanted cell populations, process-related impurities, or contaminants appropriately controlled?
Viability
Does the product contain an acceptable proportion of viable cells?
Potency
Does the product demonstrate the biological activity or functional characteristics relevant to its intended therapeutic effect?
Safety
Has the product been assessed for relevant microbiological or process-related risks?
The release testing panel should be based on these product-specific requirements rather than applying the same tests to every cell therapy.
Build Release Testing Into Process Development
A common mistake is waiting until late development to establish release assays.
Release testing methods should be considered during process development because manufacturing changes can affect the product characteristics being measured.
For example, changes in:
- Starting materials
- Culture conditions
- Expansion duration
- Processing methods
- Harvest procedures
- Cryopreservation
may influence identity, viability, phenotype, potency, or other quality attributes.
Early analytical development allows teams to understand which methods are appropriate and whether they can support later clinical or commercial use.
A useful approach is:
Process development → Product characterization → Method development → In-process testing → Release Testing → Batch disposition
This creates continuity between manufacturing knowledge and final product assessment.
Define the Role of In-Process Testing
In-process testing provides information during manufacturing, while release testing confirms whether the final product meets defined specifications.
These activities should work together.
Strong in-process controls can help identify manufacturing issues earlier, while final release testing provides a defined assessment before product disposition.
Select Analytical Methods That Are Fit for Purpose
Not every analytical method used during research will be suitable for release testing.
Release assays should be appropriate for their intended use and capable of generating reliable results.
Developers should consider:
- Specificity
- Accuracy
- Precision
- Repeatability
- Reproducibility
- Sensitivity
- Detection limits
- Robustness
- Testing turnaround time
Method development should also consider how the assay will perform across different analysts, instruments, and manufacturing batches.
As a program advances, methods may require additional qualification or validation according to their intended use and applicable requirements.
Establish Scientifically Justified Specifications
A specification defines the acceptance criteria a product must meet.
Specifications should be supported by relevant data, including:
- Product characterization
- Process development studies
- Manufacturing experience
- Clinical knowledge
- Analytical method capability
- Stability data
Setting specifications without sufficient process or product understanding can create unnecessary risks.
Specifications that are too broad may not adequately control product quality, while overly narrow specifications can increase batch failure risk without providing meaningful quality benefits.
The goal is to establish acceptance criteria that are scientifically justified and clinically relevant.
Consider Testing Timelines and Product Logistics
Cell therapies may have short shelf lives or complex cryogenic storage requirements. This can make testing turnaround time an important operational consideration.
Developers should evaluate:
- Sample preparation time
- Assay duration
- Laboratory capacity
- Data review timelines
- Out-of-specification investigations
- Sterility testing timelines
- Product storage conditions
- Batch disposition procedures
A technically strong assay that cannot deliver results within the required product timeline may create manufacturing challenges.
Testing strategies should therefore be designed around both analytical quality and operational practicality.
Integrate Good Manufacturing Practice Controls
Good Manufacturing Practice provides the quality framework that supports reliable testing and batch release.
Key controls include:
Qualified Equipment
Analytical instruments should be appropriately qualified, maintained, and monitored.
Controlled Procedures
Testing methods and sample handling procedures should be clearly documented.
Trained Personnel
Analysts should be appropriately trained and qualified.
Data Integrity
Testing data should be attributable, legible, contemporaneous, and appropriately controlled.
Deviation Management
Unexpected results should be investigated through defined quality procedures.
Change Control
Changes to methods, equipment, materials, or specifications should be assessed and managed.
These controls help ensure that release decisions are based on reliable and traceable data.
Plan for Microbiological Safety Testing
Cell therapy products may require testing for relevant microbiological risks.
Depending on the product and process, this may include:
- Sterility
- Mycoplasma
- Endotoxin
- Other product- or process-specific microbiological controls
Testing strategies should consider the timing of results, sample requirements, and whether rapid methods are appropriate for the product's manufacturing and release timeline.
Microbiological control should also extend beyond final testing through facility controls, raw material management, environmental monitoring, and in-process testing where relevant.
Prepare for Scale and Commercialization
A release strategy that works for a small number of clinical batches may require changes as production volume increases.
Commercial planning should consider:
- Laboratory throughput
- Assay automation
- Reagent supply
- Reference materials
- Method lifecycle management
- Multi-site testing
- Technology transfer
- Data systems
Developers should avoid building a testing strategy that depends on highly specialized manual steps that cannot support projected manufacturing demand.
Common Release Testing Mistakes
Treating Release Testing as the Only Quality Control
Final testing cannot compensate for a poorly controlled manufacturing process. In-process testing and process controls are equally important.
Using Methods That Are Not Fit for Purpose
Research methods may need significant development before they are suitable for controlled release testing.
Setting Specifications Too Early
Limited data can make early specifications difficult to justify.
Ignoring Testing Timelines
Long assay turnaround times can delay batch disposition or conflict with product shelf-life requirements.
Delaying Method Transfer Planning
Analytical methods may eventually need to move between development, QC, and external laboratories. Planning transfer requirements early can reduce future delays.
A Practical Release Testing Framework
Developers can build a stronger strategy using the following steps:
1. Define the target product profile.
Identify the product characteristics that matter for quality and clinical use.
2. Identify critical quality attributes.
Determine which attributes require control through testing or process monitoring.
3. Select fit-for-purpose analytical methods.
Choose methods capable of providing reliable and relevant information.
4. Establish the role of in-process testing.
Monitor important attributes before the final manufacturing stage.
5. Develop scientifically justified specifications.
Use product and process data to support acceptance criteria.
6. Consider testing turnaround times.
Ensure results can support product release timelines.
7. Apply Good Manufacturing Practice controls.
Maintain appropriate documentation, equipment, personnel, and data controls.
8. Plan for method lifecycle management.
Consider future validation, transfer, automation, and commercial scale.
Future Outlook
As cell therapies move toward broader clinical and commercial use, release strategies are likely to place greater emphasis on rapid microbiological methods, more robust potency assays, automation, digital data management, and improved integration between manufacturing and quality systems.
The direction is clear: Release Testing will increasingly depend on a deeper understanding of the manufacturing process rather than a collection of isolated final assays.
The strongest strategies will combine product knowledge, in-process testing, appropriate analytical methods, and Good Manufacturing Practice controls to support timely and confident batch disposition.
Conclusion
Building a reliable Release Testing strategy requires more than selecting a list of final assays. Developers need to understand the product's critical quality attributes, connect analytical methods with process knowledge, establish meaningful specifications, and plan for testing timelines and future scale.
Integrating in-process testing with Good Manufacturing Practice controls can provide greater visibility into manufacturing performance and strengthen confidence in final release decisions.
Xellera Therapeutics supports cell and gene therapy developers with bioanalytical testing, quality control and release testing, process development, and GMP manufacturing capabilities designed to support robust product quality strategies from development through clinical and commercial manufacturing.
Comments
Post a Comment